Compound class:
Synthetic organic
Comment: This compound is predicted to be the active version of the TLR7 agonist prodrug polvitolimod. It is claimed as compound 27 in Primmune Therapeutics' patent WO2019226977A1 [3]. TLR7 agonists are predicted to offer clinical benefit in patients with severe COVID-19 [2], since some loss-of-function variants in TLR7 are associated with increased COVID-19 disease severity (likely via blunted type I IFN production) [1]. We can make a provisional link between compound 27 and the active TLR7 agonist PRX034.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Solanich X, Vargas-Parra G, van der Made CI, Simons A, Schuurs-Hoeijmakers J, Antolí A, Del Valle J, Rocamora-Blanch G, Setién F, Esteller M et al.. (2021)
Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19. Front Immunol, 12: 719115. [PMID:34367187] |
2. Szeto MD, Maghfour J, Sivesind TE, Anderson J, Olayinka JT, Mamo A, Runion TM, Dellavalle RP. (2021)
Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment. Dermatology, 237 (6): 847-856. [PMID:34511591] |
3. Webber SE, Appleman JR. (2019)
Tlr7 agonists. Patent number: WO2019226977A1. Assignee: Primmune Therapeutics, Inc.. Priority date: 25/05/2018. Publication date: 28/11/2019. |